(Q39727725)

14 September 2017

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells (English)

1 reference

14 September 2017

1 reference

1

1 reference

14 September 2017

5

1 reference

14 September 2017

Annette T Byrne

2

0 references

author name string

Aisling E O'Connor

series ordinal

3

1 reference

PubMed ID

20229355

14 September 2017

Sharon McGee

series ordinal

4

1 reference

PubMed ID

20229355

14 September 2017

John Crown

series ordinal

6

1 reference

14 September 2017

16 March 2010

1 reference

Investigational New Drugs

14 September 2017

1 reference

14 September 2017

29

1 reference

14 September 2017

5

1 reference

14 September 2017

752-759

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-010-9415-5

14 September 2017

0 references

cites work

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Trastuzumab: triumphs and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Herceptin: mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9415-5

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

21 January 2018

1 reference

12 December 2020

Prognostic significance of the combination of biological parameters in breast cancer

1 reference

12 December 2020

Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients

1 reference

12 December 2020

Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.

1 reference

12 December 2020

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

12 December 2020

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo

1 reference

12 December 2020

Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects

1 reference

12 December 2020

10.1007/S10637-010-9415-5

Identifiers

DOI

1 reference

14 September 2017

1 reference

PubMed ID

20229355